IM-1617 / Immunome - LARVOL DELTA

Preclinical evaluation of IM-1617, a clinical-stage ADC for solid tumors (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Preclinical • Oncology • Solid Tumor

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors (Businesswire) - "The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1617. The study is expected to include participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer."

Trial status • Breast Cancer • Colorectal Cancer • Non Small Cell Lung Cancer

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=175 | Recruiting | Sponsor: Immunome, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Estrogen Receptor Positive Breast Cancer • Gastric Cancer • Head and Neck Cancer • HER2 Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • HER-2 • PD-1 • PD-L1 • PGR

Pipeline Highlights:…IM-1617 (Businesswire) - "In April 2026, Immunome received IND clearance for IM-1617 and plans to initiate a Phase 1 trial in the second quarter of 2026. IM-1617 is a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload."

IND • Trial status • Solid Tumor

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=175 | Not yet recruiting | Sponsor: Immunome, Inc.

New P1 trial • Breast Cancer • Colorectal Cancer • Esophageal Cancer • Estrogen Receptor Positive Breast Cancer • Gastric Cancer • Head and Neck Cancer • HER2 Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • HER-2 • PD-1 • PD-L1 • PGR

Immunome expects to submit INDs for IM-1617, IM-1340 and IM-1335 in early, mid, and late-2026, respectively. (Businesswire) - "The programs each pursue undisclosed solid tumor targets and incorporate HC74, Immunome’s proprietary TOP1 inhibitor payload. Additional undisclosed antibody drug conjugates (ADCs) are in discovery and lead optimization to support INDs in 2027 and beyond."

IND • Solid Tumor

Preclinical Pipeline (Businesswire) - "Immunome’s three preclinical ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, each of which incorporates HC74, continue to advance towards 2026 IND submissions."

IND • Solid Tumor

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Businesswire) - "Preclinical Pipeline: Immunome’s three preclinical ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, each of which incorporates HC74, are currently undergoing IND-enabling work."

Preclinical • Solid Tumor

Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Businesswire) - "Pipeline Highlights:...Preclinical Pipeline – Immunome’s preclinical pipeline also includes three novel ADCs against solid tumor targets, IM-1617, IM-1340 and IM-1335, which are currently undergoing IND-enabling work, and additional, undisclosed ADCs in discovery and lead optimization."

Pipeline update • Preclinical • Solid Tumor